2022: The Pivotal Year for Digital Therapeutics – Laying Foundations for Growth and Innovation

In recent years, the traditional healthcare industry has been undergoing comprehensive digital transformation. The informatization of medical processes, continuous health data recording via wearable devices, and the generation of massive biological datasets by emerging technologies are serving as fuel for artificial intelligence. Through iterative refinement of algorithmic models, AI assists physicians in disease early warning, diagnosis, treatment, monitoring, and long-term management, thereby expanding the scope of health management services from within medical institutions to the broader digital realm. Against this backdrop, the concept of Digital Therapeutics (DTx) has emerged. By leveraging digital means, DTx translates established medical principles, clinical guidelines, or standard treatment protocols into software-driven interventions. This approach effectively enhances patient adherence and accessibility in chronic disease management, overcoming the limitations of traditional pharmacological therapies.

Digital therapeutics have the potential to become a new milestone in the healthcare sector. The year 2021 was hailed as the “Year One” of digital therapeutics in China, while 2022 emerged as the “pivotal year,” marking a critical period for establishing deep roots, fostering upward growth, and enabling lateral expansion.June 16, 2022, byHosted by VCBeat, co-hosted by Taozi Health and Yuanyi CapitalofDigital Therapeutics Innovation Practice ForumThe event will be held online. VCBeat Research Institute is set to release its flagship “Global Report on Digital Therapeutics (2022),” a comprehensive nearly 100,000-word record of industry exploration. In collaboration with Weimai (Co-Chair of the DTA Asia-Pacific Policy Research Center), it will also publish the Chinese version of the “DTX Value Assessment and Integration Guide.” The event will feature insightful contributions from frontline entrepreneurs, clinical experts, and investors, providing valuable reference for the industry’s development.

Topic Highlight 1:Global Trends and Co-Creation Collaboration

In 2017, the world’s first digital therapeutic received approval from the U.S. Food and Drug Administration (FDA), bringing digital therapeutics into the public spotlight. Since the beginning of 2022, a number of leading international digital therapeutics companies—including Pear Therapeutics, Akili Interactive, Hinge Health, Noom Health, and Better Therapeutics—have announced that they have completed or are about to complete their initial public offerings (IPOs). Undoubtedly, the rapid growth of the digital therapeutics industry has far exceeded expectations. So, what is the current state of global development in digital therapeutics? What efforts has China’s industrial sector made in commercialization, and how does the industry differ between domestic and international markets? We are honored to invite Megan Coder, Founder of the Digital Therapeutics Alliance (DTA) and current DTA Chief Policy Officer, to participate in this roundtable discussion, providing a comprehensive and timely overview of the development and exploration of digital therapeutics both globally and within China.

Topic Highlight 2: Industrial Clusters and Park Development

There is no doubt that China will be the key investment area for digital therapeutics (DTx) in the future. According to data from VCBeat, a total of 33 transactions occurred in China’s DTx sector from 2019 to October 2021. An analysis of the agglomeration status of the domestic DTx industry reveals that the nascent DTx sector in China is beginning to exhibit trends of industrial clustering. Notably, DTx companies are relatively concentrated in Beijing, Shanghai, and Hangzhou, reflecting the “software + internet” nature of digital therapeutics. The Dolphin Digital Medical Industrial Park is committed to building China’s most influential digital health technology innovation hub and has become the preferred destination for investments in digital health and internet hospitals.At the same time,Seagull Digital Medical Device Industrial Park will build a digital healthcare industrial park driven by the dual cores of internet healthcare and digital therapeutics products, providing end-to-end application services for enterprises with digital therapeutics products and attracting the agglomeration and development of digital healthcare-related enterprises and institutions.

Topic Highlight 3: Application Scenarios and Technological Advancements

Digital therapeutics is a recognized multidisciplinary field. Beyond software technology, it encompasses a wide array of digital technologies, including wireless networks, sensors, microprocessors and integrated circuits, artificial intelligence, cloud computing and big data, and VR/AR/MR technologies. The empowerment provided by these digital technologies lays the foundation for the development and implementation of digital therapeutics products. This forum will also invite numerous distinguished experts to elucidate the development and advancements of digital therapeutics from the perspective of technological empowerment.

—

Digital Therapeutics Innovation Practice Forum

Forum Date: June 16, 2022

Forum Organizers: VB100, VCBeat, Dongmaicheng, VCBeat Institute

Co-hosted by: Taozi Health, Yuanyi Capital

Report Release

09:00-09:20

2022: A Pivotal Moment for Digital Therapeutics

——Three Major Questions About Digital Therapeutics and Reflections

Jiang Tianjiao | Dean of VCBeat Institute

Exploration and Practice

09:20-09:40

Closed-Source Digital Intervention Technology

Zhang Jing | CEO, Senmei Medical

09:40-10:00

The Global Landscape of Digital Therapeutics Innovation from the Perspective of Amazon Web Services

Li Jian | Chief Business Director, Greater China, Amazon Web Services (AWS), Healthcare and Life Sciences Industry

10:00-10：20

The Transformation of Digital Precision Management in Oncology

Chen Kaishen | Founder and CEO of Zhongxi Medical Technology

10:20-10：40

Exploring the Value of Digital Therapeutics in Traditional Chinese Medicine for Rheumatism

Hou Liping | President of Taiyuan Hou Liping Traditional Chinese Medicine Hospital for Rheumatic and Bone Diseases

10：40-11:00

Empowering the Digital and Intelligent Transformation of Musculoskeletal Rehabilitation: The Application of Smart Sensors in Digital Therapeutics

Zhou Kaibo | CTO, Fudong Medical

Trend Outlook

14:00-14:20

Digital Therapeutics: From Concept to Implementation

Yang Ruirong | Partner at Yuanyi Capital

Park Development

14:20-14:40

From Efficient Construction to Operational Empowerment: Sharing Success Stories of the Dolphin Digital Medical Industrial Park

Chen Jingbo | Vice President, Dolphin Digital Medical Industrial Park

14:40-15:00

Dual-Core Drive: Sharing the Path to Efficient Development of Digital Therapeutics

Mao Chaolan | Executive Director, Seagull Digital Medical Device Industrial Park

Co-Creation and Collaboration

15:00-15:30

Global Digital Therapeutics Connection and Joint Release of the "DTA Guidelines for Value Assessment and Integrated Application of Digital Therapeutics"

Megan Coder | Founder of DTA, Current Chief Policy Officer at DTA

Bai Yan | Director of Strategic Investment Department at Weimai, Co-Chair of DTA Asia Research Center

Chen Peng | Senior Researcher at VCBeat Institute, Senior Editor at VCBeat

15:30-16：20

Expert Roundtable: How Digital Therapeutics Effectively Bridge the Healthcare Chain and Deeply Empower Upstream and Downstream Industries

Moderator: Bi Yuanfeng | Co-founder and COO of VCBeat

Xia Wenrong | Innovation Director, Digital Department, Sanofi

Wu Hao | CEO, Taozi Health

Wang Li | Founding Partner, Heda Capital

Zhang Jing | CEO, Senmei Medical